Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2001
Business Overview: The Company operates in two segments: Animal Health Products and Research & Development (R&D). Its primary customers are in the U.S. and foreign dairy and beef industries. Key products include FIRST DEFENSE(R), KAMAR(R) HEATMOUNT(R) DETECTOR, and WIPE OUT(R) DAIRY WIPES.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $3,325,376 | $2,905,905 |
| Net Profit After Taxes | $221,538 | $291,447 |
| Net Profit Per Share (Diluted) | $0.08 | $0.10 |
| Cash and Cash Equivalents | $1,476,046 | $1,785,153 |
| Net Cash Provided by Operating Activities | $281,591 | $(294,483) |
| Total Debt (Current + Long Term) | $424,588 | $434,659 |
| Gross Margin (Product Sales) | 50% | 51% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 14% ($419,000) year-over-year for the six-month period, driven by a 13% increase in product sales.
- Profitability Decline: Despite revenue growth, Net Profit After Taxes decreased 24% ($70,000) compared to the prior year. This was primarily due to a non-cash tax expense of $147,040 recorded in 2001 (absent in 2000) following the release of a valuation allowance on deferred tax assets.
- Cash Flow Improvement: Operating cash flow turned positive, providing $281,591 compared to a usage of $294,483 in the prior year, largely due to improved working capital management (increase in accounts payable) and the tax benefit adjustment.
- Capital Expenditures: Investing cash outflows surged to $742,968 (from $53,279) due to a facility addition ($650,000 estimated) to address production backlogs and new manufacturing equipment.
- Backlog: A significant backlog of orders for FIRST DEFENSE(R) reached approximately $1,000,000 as of June 30, 2001, compared to no material backlog in 2000.
Guidance, Outlook, and Risks
- Production Capacity: A 5,300 sq. ft. facility addition was completed in May 2001 to address the $1,000,000 order backlog, which management intends to fill by year-end.
- R&D Strategy: The Company targets investing 10% to 13% of product sales in R&D (net of grants/licensing). Significant investment is being made in MAST OUT(TM), a mastitis treatment requiring FDA approval, which may temporarily impact quarterly profitability.
- Licensing and Grants:
- Received a $400,000 grant from the Maine Technology Institute and $196,000 from the NIH for MAST OUT development (recorded as deferred revenue due to contingent repayment).
- Licensed DIFFGAM rights to Novatreat Ltd for $100,000 total (recognized over 22 months).
- Sold an option for a 50% interest in AgriCell Company, LLC for $100,000.
- Liquidity: Management believes current capital resources are sufficient to meet working capital requirements for the next 12 months.
- Risks: Forward-looking statements are subject to risks regarding regulatory approvals (FDA), production delays, and competition. The Company faces state regulatory barriers for the TIP-TEST(TM): JOHNE'S product.
Investor Verification Checklist
- Backlog Realization: Verify if the $1,000,000 FIRST DEFENSE(R) backlog is converted to revenue by year-end 2001 as projected.
- Tax Expense Recurrence: Confirm the nature of the $147,040 tax expense and whether it represents a one-time adjustment or a recurring liability.
- MAST OUT(TM) Progress: Monitor FDA approval timelines and associated costs, as these could exceed the targeted 10-13% R&D expense ratio.
- Grant Contingencies: Review the terms of the Maine Technology Institute grant, specifically the repayment obligation of up to $800,000 (2% of sales) upon commercialization.
- Capital Expenditure ROI: Assess the return on the $650,000 facility expansion and $250,000 equipment investment in future quarters.